Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive

This publication has 11 references indexed in Scilit:

• Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel: a randomized trial
  Human Reproduction, 2005
• Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring
  Obstetrics & Gynecology, 2002
• Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol
  American Journal of Obstetrics and Gynecology, 2002
• Pharmacokinetics of a contraceptive patch (Evra^™/Ortho Evra^™) containing norelgestromin and ethinyloestradiol at four application sites
  British Journal of Clinical Pharmacology, 2002
• Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants
  Contraception, 2001
• Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol
  Human Reproduction, 2001
• Pharmacokinetics of Etonogestrel and Ethinylestradiol Released from a Combined Contraceptive Vaginal Ring
  Clinical Pharmacokinetics, 2000
• Ziprasidone and the pharmacokinetics of a combined oral contraceptive
  British Journal of Clinical Pharmacology, 2000
• The Combined Oral Contraceptive Risks and Adverse Effects in Perspective
  Drug Safety, 1995
• Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation
  Contraception, 1992